One possible novel immunotherapy for head and neck cancer might be personalized cancer vaccines. These are designed based on the specific characteristics of a patient's tumor to train the immune system to recognize and attack it. Another approach could be adoptive cell therapy, where immune cells are modified outside the body and then infused back to fight the cancer.
As for head and neck tumors, because most head and neck tumors occur in the mucus membrane, more than 90% of them are positive for the receptor for the growth factor of the human skin. Target drugs such as cetuxed mainly act on the growth factor of the human skin. Cetuxed combined with chemotherapy can achieve better efficacy in the treatment of head and neck tumors and reduce tumor relapse and migration. In addition, Bevacobin, Duostat, etc. can inhibit tumor neoplasia and thus tumor growth. However, there was no specific mention of targeted drugs for head and neck adenomas. There was only information on targeted drugs for head and neck tumors. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
For patients with relapsed or metastasized head and neck cancer, the commonly used first-line chemotherapy drugs included platinum, 5 -flurfluralin, taxane, cetuxed, and methylethalin, but it was not easy to determine which drug was the "best". There are different recommended combinations for different situations and different tolerance levels: - The standard first-line treatment was platinum-based chemotherapy in combination with 5 -flurfluralin, taxane, or cetuxed. - For patients who could not tolerate 5 -fluralin, platinum/taxane in combination with cetuxed could be used; for patients who could not tolerate platinum, taxane in combination with cetuxed could be used; for patients who could not tolerate the combination therapy, platinum, taxane, methylethrin, cetuxed and other single agents could be used. - In second-line treatment, patients who had not used taxoids before could use taxoids in combination with cetuxed; patients who had not used cetuxed before could use cetuxed alone; others could use chemotherapy alone that had not been used in first-line treatment. In addition, in the rhythmic chemotherapy protocol, methylethalin could be used as a commonly used oral chemotherapy drug for head and neck cancer. In short, the choice of chemotherapy drugs needed to take into account the patient's general condition, tumor location, tumor stage, pathological type, and other factors, weighing the pros and cons of the treatment method. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Different types of targeted drugs had different side effects. If it was a targeted drug with a positive expression of HER - 2, the main side effect might be diarrhea. If it was combined with other chemotherapy drugs, it might also cause white blood cell and Platelet decrease, fatigue, etc.; Monocentric antibody-targeted drugs may cause side effects such as high blood pressure, proteuria, liver and kidney function abnormalities; Tyrosinase kinases that target gene mutations may cause side effects such as rash, itching, mucus membrane inflammation, oral ulcers, diarrhea, etc. In addition, targeted drugs generally may also have digestive toxicity, such as loss of appetite, nausea, abdominal distension, abdominal pain, vomiting, diarrhea, etc.; general allergic reactions such as skin itching, redness, hair loss, blackening of nails, cracks, peeling, chapped skin, and general rashes; liver toxicity such as increased body indicators such as direct Bilirubin, indirect Bilirubin, Altaic Pyrutanase, etc.; cardiovascular reactions such as increased blood pressure, proteinuria, etc., as well as damage to the skin, such as decreased skin resistance. There were pustules, itchy skin, chapped skin, abnormal nails, and hair loss. However, there was no specific description of the side effects of targeted drugs for head and neck cancer. The side effects might cover these aspects. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
One success story is that of melanoma patients. Immunotherapy has significantly improved the survival rate for many melanoma patients. For example, some patients who had advanced melanoma with no other treatment options saw their tumors shrink or even disappear completely after receiving immunotherapy drugs like pembrolizumab. This has not only extended their lives but also improved their quality of life.
One success story is that of melanoma patients. Immunotherapy drugs like ipilimumab have significantly increased the survival rate of melanoma patients. It works by activating the immune system to recognize and attack cancer cells.
There's a case where a patient's kidney cancer was resistant to traditional treatments. However, with immunotherapy, the patient's immune system got a boost and started attacking the cancer cells. Eventually, the patient achieved long - term remission.
A middle - aged patient with lung cancer had tried chemotherapy with little success and many side effects. When they switched to immunotherapy, their body started to respond positively. Their symptoms like shortness of breath and fatigue decreased. Over time, the cancer cells in their lungs were being controlled by their own immune system, which was activated by the immunotherapy. This success story shows how immunotherapy can be a game - changer for lung cancer patients who do not respond well to traditional treatments.
Sure. There are cases in bladder cancer. Some patients with advanced bladder cancer who received immunotherapy had positive results. The immune - enhancing drugs helped in controlling the spread of the cancer. For instance, atezolizumab has been effective for some patients, providing them with more time and a better state of health compared to traditional treatments alone.
Another example is in bladder cancer. Immunotherapies have been used to treat advanced bladder cancer. By boosting the immune system's response, some patients have experienced long - term remissions. The immune system is able to target the cancer cells specifically, which is different from traditional treatments that may affect healthy cells as well. This targeted approach is what makes immunotherapy so promising in bladder cancer treatment.
Sure. There was a patient who had advanced kidney cancer. After starting immunotherapy, within a few months, the tumor size started to shrink significantly. His overall health also improved, and he was able to resume some normal daily activities that he couldn't do before due to the cancer.